Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.07.04.20146548; this version posted July 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea Min Ho An, MD1,4*, Min Seo Kim, MD2,5*, Yu-Kyung Park, MD3, Bong-Ok Kim, MD, PhD3, Seok Ho Kang, MD9, PhD, Won Jun Kim, MD2, Sung Kyu Park, MD3, Hea-Woon Park, MD, PhD3, Wonjong Yang, MD3, Joonyoung Jang, MD3, Soon-Woo Jang, MD, KMD6,10, Tae-Ho Hwang, DSS, PhD7,8 *two authors contributed equally to this work 1 Ajou University, School of Medicine, Suwon, Republic of Korea 2 Korea University, College of Medicine, Seoul, Republic of Korea 3 Korea Workers’ Compensation & Welfare Services Daegu Hospital, 515 Hakjeong-ro, Buk-gu, Daegu, Republic of Korea 4 Director of So Ahn Public Health Center, Wando, Republic of Korea 5 Director of Cheongsan Public Health Center, Wando, Republic of Korea 6 Director of Bukha Public Health Center, Jangseong, Republic of Korea 7 Department of Pharmacology, Pusan National University, School of Medicine, Yangsan, Republic of Korea 8 Gene and Cell Therapy Research Center for Vessel-associated Diseases, School of Medicine, Pusan National University, Yangsan, Republic of Korea 9 Department of Urology, Korea University, School of Medicine, Seoul, Republic of Korea 10 Pusan University, School of Medicine, Yangsan, Republic of Korea Corresponding author: Soon-Woo Jang, MD, KMD6,10 Pusan University, School of Medicine, Yangsan, Republic of Korea Director of Bukha Public Health Center, Jangseong, Republic of Korea Phone : +82-10-88994593 E-mail : kmedicsoon@gmail.com Tae-Ho Hwang, DSS, PhD7,8 Department of pharmacology, Pusan National University, School of Medicine, Yangsan, Republic of Korea Director of Gene and Cell Therapy Research Center for Vessel-associated Diseases, School of Medicine, Pusan National University, Yangsan, Republic of Korea Phone: +82-10-71579950 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. E-mail : thhwang@pusan.ac.kr medRxiv preprint doi: https://doi.org/10.1101/2020.07.04.20146548; this version posted July 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Keywords: COVID-19, Hydroxychloroquine, antibiotics, azithromycin, treatment response, retrospective cohort study. Short-Running Title: Response to pharmacological treatment of COVID-19 Total word count: abstract(235), total manuscript without abstract(2411) Number of figures: 2 Number of tables: 3 Number of supplementary figures and tables: 1 Funding: The authors received no funding for this investigation Declaration of Conflicting interest The authors have no competing interests to disclose Abstract Objectives: To assess the efficacy of hydroxychloroquine on mild-moderate COVID-19 patients in South Korea. Methods: A retrospective cohort study of the 358 laboratory-confirmed SARS-CoV-2 (COVID-19) patients was conducted. 226 patients met inclusion criteria for..